Dapagliflozin/Glimepiride/Metformin
AssetAlso DGM FDC
Combines increased urinary glucose excretion, stimulated insulin secretion, and reduced hepatic glucose production to improve glycemic control.
- Stage
- Stage not known
- Modality
- Small molecule
- Target
- SLC5A2
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
0In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.